Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGIC-2: Sequential Encorafenib/Binimetinib Combinations in BRAF V600 Melanoma
NCT02159066Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2014
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of encorafenib, binimetinib in melanoma, sponsored by Pfizer. Started Jul 2014; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02159066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159066.